Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer

Sponsor
Peking University Third Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03857737
Collaborator
(none)
300
1
2
130
2.3

Study Details

Study Description

Brief Summary

In this study, patients who are going to undergo endoscopic submucosal dissection (ESD) or surgery for early gastric cancer will be enrolled and divided into ESD group and Surgery group according to the procedure they go through. The patients will be followed up for at least 5 years after ESD or surgery. Esophagogastroduodenoscopy (EDG) and biopsy will be performed 3 months and then 6 months after ESD or surgery. Thereafter, EDG will be performed along with biopsy and abdominal computed tomography annually up to 5 years. Patients' data such as age, sex, clinical diagnosis, achievement of en-bloc resection, pathological outcomes, complications and survival condition will be prospectively collected. Statistical methods such as Student's t-test, the chi-square test, the Kaplan-Meier method and the log-rank test will be used to compare the short term and long term outcomes between the ESD group and the surgery group.

Condition or Disease Intervention/Treatment Phase
  • Procedure: endoscopic submucosal dissection
  • Procedure: Surgery
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Study Which Compares the Long Term and Short Term Outcomes Between Endoscopic Submucosal Dissection and Surgery in the Treatment of Early Gastric Cancer
Anticipated Study Start Date :
Mar 1, 2019
Anticipated Primary Completion Date :
Dec 31, 2029
Anticipated Study Completion Date :
Dec 31, 2029

Arms and Interventions

Arm Intervention/Treatment
Experimental: ESD group

This group include patients who are going to undergo endoscopic submucosal dissection for early gastric cancer.

Procedure: endoscopic submucosal dissection
Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.

Active Comparator: Surgery group

This group include patients who are going to undergo surgery for early gastric cancer.

Procedure: Surgery
Surgery for EGC include Distal, proximal, or total gastrectomy, which will be performed according to the location and macroscopic tumor type by experienced surgeons.

Outcome Measures

Primary Outcome Measures

  1. 5-year OS [From March 1 2019 to December 1 2024]

    5-year OS is the five year overall survival of each individual group. It will be estimated by Kaplan-Meier method, and statistical significance of differences between the two groups will be assessed using the log-rank test.

  2. 5-year DSS [From March 1 2019 to December 1 2024]

    5-year DSS is the five year disease specific survival of each individual group. It will be estimated by Kaplan-Meier method, and statistical significance of differences between the two groups will be assessed using the log-rank test.

Secondary Outcome Measures

  1. Complication [From March 1 2019 to December 1 2024]

    Complications were classified according to the Clavien-Dindo classification and the frequency of the complications will be compared between the two groups.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinically diagnosed as early gastric cancer

  • Willing to undergo endoscopic submucosal dissection or surgery for the treatment of early gastric cancer

Exclusion Criteria:
  • Advanced stage gastric cancer

  • Not willing to undergo endoscopic submucosal dissection or surgery for the treatment of early gastric cancer

  • Not willing to participate in this study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking University Third Hospital Beijing Beijing China 100091

Sponsors and Collaborators

  • Peking University Third Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Shigang Ding, Attending, Chief of the Gastrointestinal Department of Peking University Third Hospital, Peking University Third Hospital
ClinicalTrials.gov Identifier:
NCT03857737
Other Study ID Numbers:
  • PUTH020301ESD
First Posted:
Feb 28, 2019
Last Update Posted:
Feb 28, 2019
Last Verified:
Feb 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Shigang Ding, Attending, Chief of the Gastrointestinal Department of Peking University Third Hospital, Peking University Third Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 28, 2019